{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-262509","form_type":"8-K","ticker":"SNDX","cik":"0001395937","company_name":"Syndax Pharmaceuticals Inc","filed_at":"2025-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.298326+00:00","generated_at":"2026-05-17T00:50:55.091836+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Syndax reports Q3 2025 revenue $45.9M, Revuforj net sales $32M; FDA approval for NPM1m AML on Oct 24","bullets":["Total revenue $45.9M (Revuforj net $32.0M, +12% vs Q2; Niktimvo collab $13.9M).","Net loss $60.7M ($0.70/sh) vs $84.1M ($0.98/sh) year-ago; cash $456.1M.","Revuforj FDA-approved for R/R NPM1m AML Oct 24, 2025; added to NCCN Guidelines as cat 2A.","Full-year 2025 R&D+SG&A guidance narrowed to $380-$385M; expects to reach profitability.","Total Revuforj prescriptions ~850 in Q3 (+25% vs Q2); Niktimvo net sales reported by Incyte $45.8M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-262509","json":"https://secwatch.observer/filing/0001193125-25-262509.json","markdown":"https://secwatch.observer/filing/0001193125-25-262509.md","text":"https://secwatch.observer/filing/0001193125-25-262509.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1395937/000119312525262509/0001193125-25-262509-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1395937/000119312525262509/sndx-20251103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:50:55.091836+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}